1 March 2026·PIB

Dr Jitendra Singh inaugurates Central Facility for Recombinant Cells and Sensors at BRIC-RGCB Thiruvananthapuram, Keralam; developed at a cost of approximately Rs 60 cr, the new facility promises to boost Drug Discovery ...

In this note

1. At a Glance

A ₹60 crore state-of-the-art Central Facility for Recombinant Cells and Sensors inaugurated at BRIC-Rajiv Gandhi Centre for Biotechnology (RGCB), Akkulam, Thiruvananthapuram, on 1 March 2026 (National Science Day) [1].
Anchors India's push under the BioE3 Policy towards a $300 billion bioeconomy by 2030 and signals the operationalisation of the BRIC umbrella for DBT institutes [1][2].
Relevance: GS-III (Sci-Tech, Biotechnology, Indigenisation), Prelims (institutions, policies, schemes).

On 1 March 2026, Union MoS (IC) S&T Dr Jitendra Singh inaugurated the facility and announced a parallel GMP facility for CAR-T and cell-based therapies at BRIC-RGCB [1].
Pegged to India's biotech leap: biotech start-ups grew from ~50 to >11,000 in 11 years; bioeconomy grew 16-fold in a decade [1][2].

RGCB, Thiruvananthapuram — autonomous institute under Department of Biotechnology (DBT), Ministry of S&T.
BRIC (Biotechnology Research and Innovation Council) — created by DBT as an apex umbrella body amalgamating 14 autonomous DBT institutes; First Foundation Day celebrated 9–10 Nov 2024 [3].
BioE3 (Biotechnology for Economy, Environment & Employment) Policy — approved by Union Cabinet in August 2024 to foster high-performance biomanufacturing [2].
Bioeconomy trajectory: $10 bn (2014) → $165.7 bn (2024) → target $300 bn (2030) [2].

Facility: Central Facility for Recombinant Cells and Sensors [1].
Cost: ~₹60 crore [1].
Location: BRIC-RGCB Akkulam campus, Thiruvananthapuram, Kerala [1].
Parent ministry: Ministry of Science & Technology → Department of Biotechnology (DBT) [1].
Umbrella body: BRIC (Biotechnology Research and Innovation Council) [3].
Mandate: Drug discovery, medical genomics, agricultural genomics, biosensors [1].
Companion GMP facility: Two-phase project, total DBT investment ₹80 crore, for CAR-T and cell-based therapy pre-commercial production; "pay-and-use" model for industry [1].
Inaugurated on: 1 March 2026 (National Science Day) [1].
Policy backbone: BioE3 Policy, 2024 [2].

Scientific / Technological

Recombinant DNA cell platforms + biosensors → critical infrastructure for drug screening, vaccine candidates, agri-biotech traits [1].
GMP unit enables indigenous CAR-T cell therapy scale-up — India is among the first developing economies with sovereign CAR-T capacity [1].

Economic

Aligns with $300 bn bioeconomy target by 2030 under BioE3 [2].
Pay-and-use model lowers entry barrier for >11,000 biotech start-ups [1].
Bioeconomy share grew 16-fold in 10 years ($10 bn → $165.7 bn) [2].

Administrative / Governance

Demonstrates BRIC consolidation model — single governance shell over 14 DBT institutes for resource pooling [3].
Industry-academia bridge via GMP "pay-and-use" model [1].

Social / Health

CAR-T therapies target haematological cancers; domestic GMP scale-up reduces dependence on costly Western imports [1].
Located in Kerala, leveraging the state's clinical research ecosystem [1].

Aug 2024 — Union Cabinet approved BioE3 Policy [2].
Nov 2024 — First BRIC Foundation Day celebrated [3].
2024 — Bioeconomy reached $165.7 bn [2].
1 Mar 2026 — Central Facility for Recombinant Cells and Sensors inaugurated at BRIC-RGCB [1].
1 Mar 2026 — Announcement of new GMP facility (₹80 cr, two phases) for CAR-T at BRIC-RGCB [1].

Central Facility for Recombinant Cells and Sensors is at BRIC-RGCB, Thiruvananthapuram [1].
Cost of the facility: ~₹60 crore [1].
Inaugurated on National Science Day, 1 March 2026 [1].
Inaugurated by Dr Jitendra Singh, MoS (IC) S&T [1].
RGCB falls under DBT, Ministry of S&T — not Ministry of Health [1].
BRIC = Biotechnology Research and Innovation Council; umbrella for 14 DBT autonomous institutes [3].
BioE3 stands for Biotechnology for Economy, Environment and Employment [2].
BioE3 Policy approved by Cabinet in August 2024 [2].
India's bioeconomy: $10 bn (2014) → $165.7 bn (2024) [2].
Bioeconomy target under BioE3: $300 billion by 2030 [2].
New GMP facility at BRIC-RGCB → CAR-T cell therapy; total outlay ₹80 cr in two phases [1].
Operating model for GMP unit: "pay-and-use" for biotech industry [1].
Biotech start-ups in India: grew from ~50 to >11,000 in 11 years [1].

GS-III: Science & Technology — "Developments and their applications and effects in everyday life"; Indigenisation of technology; biotechnology.
GS-II: Government policies and interventions (BioE3); Health (CAR-T therapy access).
Plausible stems: 1. "Examine how the BioE3 Policy and supporting infrastructure such as BRIC-RGCB facilities can transform India into a global biomanufacturing hub." 2. "Indigenous CAR-T cell therapy production marks a paradigm shift in India's cancer care. Discuss the enabling ecosystem and remaining bottlenecks." 3. "Critically analyse India's bioeconomy growth trajectory from $10 bn (2014) to a $300 bn target (2030)."

BioE3 Policy 2024 — direct parent policy framework [2].
BIRAC & Biofoundry Network — operational arms for biotech innovation.
CAR-T cell therapy (NexCAR19) — IIT Bombay–Tata Memorial indigenous approval (2023).
National Biotechnology Development Strategy — precursor framework.
GM crops & Genome-edited crops regulation — agri-genomics linkage.
National Research Foundation (Anusandhan NRF) — overarching R&D financing body.
Biosafety levels & GEAC — regulatory backdrop for recombinant work.
PRIP / Bulk Drug Parks — pharma manufacturing complementarities.

RGCB is under DBT (S&T Ministry), not Ministry of Health/ICMR.
BRIC ≠ BRICS; BRIC here is the DBT umbrella, not the geopolitical bloc.
BioE3's "E3" = Economy, Environment, Employment — not "Energy".
Bioeconomy target is $300 bn by 2030, not 2025 or 2047.
GMP facility cost (₹80 cr) is distinct from the Recombinant Cells facility (₹60 cr).
National Science Day = 28 February generally; this inauguration occurred on 1 March 2026 (the day after) — do not equate.